Imaging Eye Structures With a Hyperspectral Camera in Healthy and Diseased Eyes
Tests a new camera imaging the retina in healthy adults and people with eye disease.
Plain-language title generated from the registry record
Registry title: Defining Retinal Structures Using Hyperspectral Retinal Imaging
Key facts
- Where
- Melbourne, AustraliaSee the site
Where in Australia
- The Centre for Eye Research AustraliaMelbourne, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Center for Eye Research Australia
- Trial code
- NCT07555574
- Record updated
- 29 April 2026
- Original description
This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease. Hyperspectral imaging captures retinal data across multiple wavelengths to generate detailed spectral information that may reveal features not visible with conventional retinal photography.Read full original descriptionShow less
Defining Retinal Structures Using Hyperspectral Retinal Imaging
This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease. Hyperspectral imaging captures retinal data across multiple wavelengths to generate detailed spectral information that may reveal features not visible with conventional retinal photography.
Approximately 1000 participants will undergo multi-modal ophthalmic imaging in Melbourne, Australia, including hyperspectral imaging, OCT, fundus photography, and related tests. The study aims to compare hyperspectral imaging with standard imaging methods and assess its ability to identify retinal biomarkers associated with diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration.
Inclusion: Adults aged 18 years and older; Able to provide informed consent; Willing and able to attend a study visit at the Centre for Eye Research Australia; Participants with diagnosed retinal or optic nerve disease (e.g., diabetic retinopathy, glaucoma, age-related macular degeneration); Age- and sex-matched healthy control participants without known retinal or optic nerve disease.
Exclusion: Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage); History of narrow anterior chamber angle or risk of angle closure glaucoma where dilation is considered unsafe; Any condition that, in the investigator's opinion, would compromise participant safety or image quality; Inability to provide informed consent; Known contraindication to pharmacological pupil dilation.